8.87
1.11%
-0.10
After Hours:
8.85
-0.02
-0.23%
Phathom Pharmaceuticals Inc stock is traded at $8.87, with a volume of 420.05K.
It is down -1.11% in the last 24 hours and down -48.67% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$8.97
Open:
$8.9
24h Volume:
420.05K
Relative Volume:
0.33
Market Cap:
$606.51M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-2.0251
EPS:
-4.38
Net Cash Flow:
$-216.95M
1W Performance:
-5.03%
1M Performance:
-48.67%
6M Performance:
-12.00%
1Y Performance:
+24.93%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
8.87 | 606.51M | 0 | -297.11M | -216.95M | -5.19 |
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-03-24 | Initiated | Stifel | Buy |
Jan-05-24 | Reiterated | Needham | Buy |
Aug-09-23 | Initiated | H.C. Wainwright | Buy |
May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-13-23 | Initiated | Craig Hallum | Buy |
Oct-21-22 | Initiated | Jefferies | Buy |
May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
May-12-21 | Upgrade | Goldman | Sell → Neutral |
Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
Feb-02-21 | Initiated | Guggenheim | Buy |
Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
Nov-20-19 | Initiated | Evercore ISI | Outperform |
Nov-19-19 | Initiated | Goldman | Neutral |
Nov-19-19 | Initiated | Jefferies | Buy |
Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Wasatch Advisors LP Invests $4.47 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.5%Should You Sell? - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Short Interest Update - MarketBeat
Eagle Asset Management Inc. Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN
Phathom Pharmaceuticals - The Healthcare Technology Report.
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register
Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Phathom Pharmaceuticals Reports Significant Revenue Growth - TipRanks
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Phathom Pharmaceuticals maintains $28 target, Buy rating - Investing.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Previ - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
Jennison Associates LLC's Strategic Acquisition in Phathom Pharm - GuruFocus.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% - Yahoo Finance
Phathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action InvestigationPHAT - Marketscreener.com
Phathom Pharmaceuticals to Report Third Quarter 2024 - GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business - The Bakersfield Californian
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the - GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - Yahoo Finance
Where are the Opportunities in (PHAT) - Stock Traders Daily
Some of the Gastroesophageal Reflux Disease Therapeutics market players are: - InsightAce Analytic
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Creative Planning Has $278,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 6.8%Time to Buy? - MarketBeat
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2024. - Marketscreener.com
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
A year in review: Phathom Pharmaceuticals Inc (PHAT)’s performance in the last year - US Post News
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.4%Time to Sell? - MarketBeat
PHAT’s 52-Week Rollercoaster: From $6.07 to $19.71 – What’s Next for Investors? - The InvestChronicle
Financial Health Report: Phathom Pharmaceuticals Inc (PHAT)’s Ratios Tell a Tale - The Dwinnex
Learn to Evaluate (PHAT) using the Charts - Stock Traders Daily
A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News
PHAT Stock Sees Decline of Approximately -13.44% in Last Five Days - Knox Daily
PHAT Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
PHAT (Phathom Pharmaceuticals Inc) may reap gains as insiders became active recently - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.5%Here's What Happened - MarketBeat
Daily Market Movement: Phathom Pharmaceuticals Inc (PHAT) Sees a -4.96 Decrease, Closing at 17.25 - The Dwinnex
A new trading data show Phathom Pharmaceuticals Inc (PHAT) is showing positive returns. - SETE News
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):